##### Table of Contents



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 WASHINGTON, D.C. 20549
 FORM 10-K
 þ
    
    ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 For the fiscal year ended December 31, 2009
 or
 o
    
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 For the transition period from  to
 COMMISSION
FILE NUMBER: 0 - 22083
 GLOBAL MED TECHNOLOGIES, INC.
  Colorado
    
    84-1116894(State or other jurisdiction of 
incorporation or organization)
    
    (I.R.S. Employer
Identification No.)
 12600 West Colfax,
Suite C-420, Lakewood, Colorado 80215(Address of principal executive
offices) (Zip Code)
     o þ
 o þ
  þ o
 o o
 þ
  Large accelerated filer o
    
    Accelerated filer o
    
    Non-accelerated filer o
    
    Smaller reporting company þ(Do not check if a smaller reporting company)
  o þ




---



##### Table of Contents



GLOBAL MED TECHNOLOGIES, INC.
FORM 10-K
December 31, 2009
 TABLE OF CONTENTS
 Item
    
    PagePART I1. Business
    
    
    41A. Risk Factors
    
    
    81B. Unresolved Staff Comments
    
    
    142. Properties
    
    
    143. Legal Proceedings
    
    
    144. (Removed and Reserved)
    
    
    16PART II5. Market for Registrants Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
    
    
    166. Selected Financial Data
    
    
    187. Managements Discussion and Analysis of Financial Condition and Results of Operations
    
    
    187A. Quantitative and Qualitative Disclosures About Market Risk
    
    
    278. Financial Statements and Supplementary Data
    
    
    279. Changes In and Disagreements with Accountants on Accounting and Financial Disclosure
    
    
    589A. Controls and Procedures
    
    
    589B. Other Information
    
    
    59PART III10. Directors, Executive Officers and Corporate Governance
    
    
    6011. Executive Compensation
    
    
    6412. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
    
    
    6913. Certain Relationships, Related Transactions and Director Independence
    
    
    71
 1




---



##### Table of Contents



Item
    
    Page14. Principal Accountant Fees and Services
    
    
    71PART IV15. Exhibits, Financial Statements, Schedules
    
    
    73SIGNATURES
    
    
    77EX-21.1EX-23.1EX-31.1EX-31.2EX-32.1EX-32.2EX-99.1EX-99.2
  2




---



##### Table of Contents



FORWARD-LOOKING STATEMENTS
 This Annual Report on Form 10-K, including Managements Discussion and Analysis of Financial
Condition and Results of Operations, contains certain forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933, as amended (1933 Act), and Section 21E of the
Securities Exchange Act of 1934, as amended (1934 Act), and Global Med Technologies, Inc.
(Global Med) intends that such forward-looking statements be subject to the safe harbors for such
statements under such sections. Our forward-looking statements include, among other things, the
plans and objectives of management for future operations of companies acquired during 2009, our
plans and objectives relating to our business strategy, our planned product enhancements and new
product development, our planned marketing efforts and the future economic performance of Global
Med These forward-looking statements are (1) identified by the use of terms and phrases such as
believe, expect, anticipate, assume, will, should, could, intend, plan,
estimate, objective, goal and other similar words and expressions, and (2) are subject to
risks and uncertainties and represent our current expectations or beliefs concerning future events.
Global Med cautions that the forward-looking statements are qualified by important factors that
could cause actual results to differ materially from those in the forward-looking statements.
These risks, uncertainties and other factors are described throughout this Annual Report on Form
10-K and include those outlined in Part I, Item 1A RISK FACTORS. Many of these factors are beyond
our control. Our forward-looking statements represent estimates and assumptions only as of the
date of this Annual Report on Form 10-K. Except as required by law, we undertake no obligation to
update any forward-looking statement to reflect events or circumstances occurring after the date of
this Annual Report on Form 10-K.
 3




---



##### Table of Contents



PART I
 
 ITEM 1. DESCRIPTION OF BUSINESS
 Overview
    Significant Developments
  Merger
 4




---



##### Table of Contents



Principal Products and Their Markets
  Ò
  LIS
 5




---



##### Table of Contents



Government Approval and Regulation
     6




---



##### Table of Contents



Competition
  Sales and Marketing
   Customers
  7




---



##### Table of Contents



Employees
  Available Information
   
 ITEM 1A. RISK FACTORS
  Risks Related to the Haemonetics Offer and the Merger
 The delay or failure to consummate the Offer or the Merger with Haemonetics could materially and
adversely affect our results of operations and our stock price.
  
    
    the attention of our management and our employees may be diverted from day-to-day operations as they focus on consummating the Merger;
    
    the Merger Agreement places a variety of restrictions and constraints on the conduct of our business outside of the ordinary course prior to the closing of the Merger or the termination of the Merger Agreement;
 8




---



##### Table of Contents




    
    the pending Offer and the Merger may generate uncertainty among our customers; and
    
    our ability to attract new employees and retain our existing employees may be
harmed by uncertainties associated with the Merger, and we may be required to incur substantial costs to recruit replacements for lost personnel.
   
    
    our stockholders will not receive the consideration that Haemonetics has agreed to pay pursuant to the Merger Agreement, and our stock price may decline;
 
    
    we have incurred and will incur significant transaction costs, including legal, accounting,
financial advisory and other costs relating to the Offer and Merger; and
    
    under some circumstances, we may be required to pay a $2.6 million breakup
fee to Haemonetics and reimburse Haemonetics for its expenses incurred in
connection with the transactions contemplated by the Merger Agreement up to $500,000 in the aggregate
  A purported stockholder class action lawsuit has been filed against Global Med, Haemonetics,
Acquisition Sub and members of our Board of Directors and certain officers challenging the Merger
Agreement and seeking a temporary restraining order to enjoin the Offer.
  Risks Related to Our Business
 Our reported revenue and operating results may fluctuate widely due to irregular sales cycles,
contract terms and the application of accounting rules.
  We are dependent on major channel partners to sell our products into certain markets.
  9




---



##### Table of Contents



We may not be able to realize our sales backlog as expected which could reduce our revenue and
operating results.
  Our recurring maintenance revenue could be reduced if we fail to meet service requirements.
  Our results are vulnerable to general economic conditions.
  Our cash flows from operations may fluctuate widely from quarter to quarter and our revenue and
cash receipts may not be sufficient to meet the operating needs of our business.
  10




---



##### Table of Contents



If we are unable to successfully integrate the operations of Inlog and eDonor, our revenue and
results of operations could be adversely affected.
  Our business and our software products are subject to substantial competition which may adversely
affect our ability to attract and retain customers.
  Our revenue may be dependent on our ability to update and enhance our existing products and
services and to develop new ones.
  We cannot be certain that our research and development activities will be successful.
  We depend significantly upon our intellectual property rights and the failure to protect our rights
could reduce our revenue and/or increase our operating costs.
  11




---



##### Table of Contents



Failure to comply with government regulations and requirements could preclude us from continuing to
market our existing products or introducing new products which could adversely affect our revenue
and results of operations.
  We may be subject to product liability exposure.
  We may pursue strategic acquisitions and if we are unable to successfully acquire or integrate
these companies, we may not be able to grow our revenue.
  We depend on our key personnel for the success of our business and the loss of one or more key
personnel could have an adverse effect on our ability to manage our business.
  12




---



##### Table of Contents



Risks Related to International Operations
 We face a number of risks associated with international operations
  We are subject to foreign exchange risks
  Risks Related to Our Stock
 If Penny Stock regulations impose restrictions on the marketability of our common stock, the
abilty of our shareholders to sell shares of our stock could be impaired.
  Our common stockholders could face substantial potential dilution from our Series A Convertible
Preferred Stock and outstanding stock options, warrants, unvested restricted stock and contingently
issuable shares
  13




---



##### Table of Contents



The market price of our common stock is highly volatile which may limit our investors ability to
actively trade their shares of our common stock
  We do not anticipate paying any dividends on our common stock
  
 ITEM 1B.
    
    UNRESOLVED STAFF COMMENTS
  
 ITEM 2.
    
    DESCRIPTION OF PROPERTIES
  
 ITEM 3.
    
    LEGAL PROCEEDINGS
 Global Med Technologies, Inc. v.
Donnie L. Jackson, Jr., et al
   14




---



##### Table of Contents



s
   Carmelo J. Corica, Joseph F. Sham and Robert OBrien
v. Michael Ruxin et al., Case Nos. 10CV673, 10CV801, 10CV802
 15




---



##### Table of Contents



ITEM 4.
    
    (Removed and Reserved)
 
 PART II
 
 ITEM 5. MARKET FOR REGISTRANTS COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF
EQUITY SECURITIES
 Market Information
   COMMON STOCK
 2009HIGH
    
    LOWFirst Quarter (January 2009 to March 2009)
    
    $
    0.91
    
    
    $
    0.31Second Quarter (April 2009 to June 2009)
    
    $
    0.80
    
    
    $
    0.41Third Quarter (July 2009 to September 2009)
    
    $
    1.10
    
    
    $
    0.57Fourth Quarter (October 2009 to December 2009)
    
    $
    0.92
    
    
    $
    0.60
 2008HIGH
    
    LOWFirst Quarter (January 2008 to March 2008)
    
    $
    1.31
    
    
    $
    0.75Second Quarter (April 2008 to June 2008)
    
    $
    1.58
    
    
    $
    1.03Third Quarter (July 2008 to September 2008)
    
    $
    1.49
    
    
    $
    0.96Fourth Quarter (October 2008 to December 2008)
    
    $
    1.25
    
    
    $
    0.55
  16




---



##### Table of Contents



Dividends
 Common Stock
  Preferred Stock
  Equity Compensation Plan Information
  Number of securitiesremaining available forWeighted average
    
    future issuance underNumber of securities to
    
    exercise price of
    
    equity compensationbe issued upon exercise
    
    outstanding
    
    plans (excludingof outstanding options,
    
    options, warrants
    
    securities reflected inwarrants and rights
    
    and rights
    
    column (a)(a)
    
    (b)
    
    (c)Equity compensation
plans approved by
stockholders2001 Stock Option Plan
    
    
    6,071,937
    
    
    $
    0.89
    
    
    
    4,011,242Equity compensation
plans not approved by
stockholders2003 Stock Option Plan
    
    
    50,000
    
    
    $
    1.50
    
    
    
    2,856,414Other Stock Options
    
    
    300,000
    
    
    $
    1.16
    
    
    
    Warrants
    
    
    10,072,292
    
    
    $
    0.73
    
    
    
    Total
    
    
    16,494,229
    
    
    $
    0.78
    
    
    
    6,867,656
 17




---



##### Table of Contents



ITEM 6.
    
    SELECTED FINANCIAL DATA
  
 ITEM 7.
    
    MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 The following discussion of our financial condition and results of operations should be read in
conjunction with our audited financial statements and related notes included in Part II, Item 8 of
this Annual Report on Form 10-K. This discussion contains forward-looking statements, the accuracy
of which involves risks and uncertainties. Our actual results could differ materially from those
anticipated in these forward-looking statements for many reasons, including the risks faced by us
described in Part I, Item 1A RISK FACTORS.
 GENERAL
   18




---



##### Table of Contents



Merger
  Business Strategy
   1.
    
    Direct selling to customers through our internal sales force; and
 2.
    
    Marketing and selling through Channel Partners that are established in
blood donor hospital markets.
   19




---



##### Table of Contents



Overview
        20




---



##### Table of Contents



Critical Accounting Policies and Estimates
  Revenue Recognition
 Software  Revenue Recognition Software Revenue
Recognition
     21




---



##### Table of Contents



Allowance for Doubtful Accounts
  Allocation of Acquisition Purchase Prices
  Capitalized Software Costs
  Income Tax Valuation Allowance
 Accounting for
Income Taxes
 22




---



##### Table of Contents



YEAR ENDED DECEMBER 31, 2009 COMPARED TO YEAR ENDED DECEMBER 31, 2008
 Revenues
   2009
    
    2008Maintenance
    
    
    55.1
    %
    
    
    50.5
    %Consulting services
    
    
    26.7
    %
    
    
    25.2
    %Software license fees
    
    
    16.0
    %
    
    
    21.0
    %PeopleMed
    
    
    2.2
    %
    
    
    3.3
    %Total revenue
    
    
    100
    %
    
    
    100
    %
  Cost of revenue.
 Gross profit
 General and administrative
 Legal accrual.
 Sales and marketing
 23




---



##### Table of Contents



Research and development.
 Depreciation and amortization
 Income from operations
 Interest income
 Interest expense
 Provision for income taxes.
 LIQUIDITY AND CAPITAL RESOURCES
   24




---



##### Table of Contents



OFF-BALANCE SHEET ARRANGEMENTS
  RECENTLY ISSUED FINANCIAL ACCOUNTING STANDARDS
 TM
  25




---



##### Table of Contents



(Included in Accounting Standards Codification ASC 805 Business Combination, previously known as
SFAS , Business Combinations). Business Combinations
 (Included in Accounting Standards Codification ASC 810 Consolidation, previously known as ). Noncontrolling Interests in
Consolidated Financial Statements, an amendment of ARB No. 51
 (Included in Accounting Standards Codification ASC 820 Fair Value Measurements and Disclosures,
previously known as SFAS 157, Fair Value Measurements). Fair Value Measurements and Disclosures (Topic 820): Improving Disclosures about Fair
Value Measurements Fair Value Measurements and Disclosures
 (Included in Accounting Standards Codification ASC 820 Effective Date of FASB Statement No. 157,
previously known as FASB Staff Position (FSP) SFAS No. 157-2, Effective Date of FASB Statement
No. 157). Effective Date of FASB Statement No. 157
 (Included in Accounting Standards Codification ASC 350 previously known as FSP SFAS No. 142- an
amendment of Goodwill and Other intangible Assets). Goodwill and Other intangible Assets
 26




---



##### Table of Contents



(Included in Accounting Standards Codification ASC 825 Disclosures about Fair Value of Financial
Instrument previously known as FSP 107-1 and APB 28-1 Interim Disclosures
about Fair Value of Financial Instruments, Disclosures about Fair Value
of Financial Instruments Interim Financial Reporting,
 (Included in Accounting Standards Codification ASC 855 Subsequent Events previously known SFAS
165). Subsequent Events
 (Included in Accounting Standards Update ASU 2009-13 Revenue Recognition) 605 Multiple-Deliverable Revenue
Arrangements
 
 ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
  
 ITEM 8. FINANCIAL STATEMENTS
  INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
 PageReport of Independent Registered Public Accounting Firm
    
    28Consolidated Balance Sheets as of December 31, 2009 and 2008
    
    29Consolidated Statements of Operations and Comprehensive Income (Loss) for the years ended
December 31, 2009 and 2008
    
    31Consolidated Statements of Stockholders Equity for the years ended
December 31, 2009 and 2008
    
    32Consolidated Statements of Cash Flows for the years ended
December 31, 2009 and 2008
    
    34Notes to Consolidated Financial Statements
    
    36
 27




---



##### Table of Contents



REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
    
 
 28




---



##### Table of Contents



GLOBAL MED TECHNOLOGIES, INC. AND SUBSIDIARIES
 
 CONSOLIDATED BALANCE SHEETS
 (In thousands)
 December 31,2009
    
    
    2008ASSETSCurrent Assets:Cash and cash equivalents
    
    $
    5,238
    
    
    $
    4,472Marketable securities
    
    
    267
    
    
    
    188Accounts receivable-trade, net of allowance for uncollectible accounts
of $602 and $502, in 2009 and 2008, respectively
    
    
    6,242
    
    
    
    6,257Accrued revenues, net of allowance for uncollectible accounts of
$17 and $28, in 2009 and 2008
    
    
    2,173
    
    
    
    1,617Prepaid expenses and other assets
    
    
    1,418
    
    
    
    1,692Prepaid income taxes
    
    
    62
    
    
    
    Total current assets
    
    
    15,400
    
    
    
    14,226Property and equipment, net
    
    
    1,326
    
    
    
    1,385Software, net
    
    
    3,555
    
    
    
    4,097Intangibles, net
    
    
    1,526
    
    
    
    1,642Goodwill
    
    
    8,585
    
    
    
    8,342Deferred income taxes
    
    
    415
    
    
    
    92Total assets
    
    $
    30,807
    
    
    $
    29,784
 
 29




---



##### Table of Contents



GLOBAL MED TECHNOLOGIES, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS (CONTINUED)
(In thousands except per share information (e.g. par values below))
 December 31,2009
    
    
    2008LIABILITIES AND STOCKHOLDERS EQUITYCurrent Liabilities:Accounts payable
    
    $
    1,071
    
    
    $
    1,248Accrued expenses
    
    
    5,280
    
    
    
    4,602Accrued income taxes payable
    
    
    
    
    
    
    101Deferred revenue
    
    
    6,563
    
    
    
    6,361Current portion of litigation accrual
    
    
    360
    
    
    
    347Current deferred income taxes
    
    
    956
    
    
    
    461Current portion of long-term debt, notes payable and capital
lease obligations
    
    
    1,257
    
    
    
    1,168Current portion of obligations to Inlog sellers, related party
    
    
    1,182
    
    
    
    1,167Total current liabilities
    
    
    16,669
    
    
    
    15,455Long-term debt and capital lease obligations
    
    
    5,743
    
    
    
    6,763Obligations to Inlog sellers, related party
    
    
    
    
    
    
    1,090Litigation accrual
    
    
    
    
    
    
    1,004Long-term deferred tax liability
    
    
    
    
    
    
    Other long-term liabilities
    
    
    103
    
    
    
    61Total liabilities
    
    
    22,515
    
    
    
    24,373Commitments and Contingencies (Note 11)Stockholders Equity :Convertible Preferred Stock Series A, $0.01 par value: Authorized shares  100; 5 and 6 issued and outstanding as of
December 31, 2009 and 2008, respectively
    
    
    5,060
    
    
    
    5,948Preferred Stock Series A, $0.01 par value: Authorized shares 
90; none issued or outstanding
    
    
    
    
    
    
    Convertible Preferred Stock Series BB, $0.01 par value:
Authorized shares  675; none issued or outstanding
    
    
    
    
    
    
    Preferred stock, $0.01 par value: Authorized shares  5,725;
none issued or outstanding
    
    
    
    
    
    
    Common stock, $0.01 par value: Authorized shares  90,000;
issued and outstanding shares  36,631 and 34,067 at December
31, 2009 and 2008, respectively
    
    
    366
    
    
    
    340Additional paid-in capital
    
    
    62,258
    
    
    
    60,311Accumulated deficit
    
    
    (58,301
    )
    
    
    (59,779
    )Accumulated other comprehensive loss
    
    
    (1,091
    )
    
    
    (1,409
    )Total stockholders equity
    
    
    8,292
    
    
    
    5,411Total liabilities and stockholders equity
    
    $
    30,807
    
    
    $
    29,784
  30




---



##### Table of Contents



GLOBAL MED TECHNOLOGIES, INC. AND SUBSIDIARIES
 
 CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
 (In thousands, except per share information)
 Year Ended December 31,2009
    
    
    2008RevenuesLicense fees, maintenance, and usage fees
    
    $
    22,621
    
    
    $
    16,706Implementation and consulting services
    
    
    9,167
    
    
    
    6,66331,788
    
    
    
    23,369Cost of revenuesLicense fees, maintenance and usage fees
    
    
    4,667
    
    
    
    4,280Implementation and consulting fees
    
    
    8,041
    
    
    
    4,87812,708
    
    
    
    9,158Gross profit
    
    
    19,080
    
    
    
    14,211Operating expenses:General and administrative
    
    
    6,888
    
    
    
    5,522Legal accrual reversal
    
    
    (1,004
    )
    
    
    Sales and marketing
    
    
    4,677
    
    
    
    3,895Research and development
    
    
    4,396
    
    
    
    3,824Depreciation and amortization
    
    
    1,418
    
    
    
    794Total operating expenses
    
    
    16,375
    
    
    
    14,035Income from operations
    
    
    2,705
    
    
    
    176Other income (expense):Interest income
    
    
    33
    
    
    
    115Interest expense
    
    
    (741
    )
    
    
    (411
    )Total other income (expense)
    
    
    (708
    )
    
    
    (296
    )Income before provision for income taxes
    
    
    1,997
    
    
    
    (120
    )Income tax expense
    
    
    (519
    )
    
    
    (299
    )Net income (loss)
    
    $
    1,478
    
    
    $
    (419
    )Basic and Diluted net income (loss) per common share:Basic
    
    $
    0.04
    
    
    $
    (0.01
    )Diluted
    
    $
    0.03
    
    
    $
    (0.01
    )Weighted average number of common shares outstanding:Basic
    
    
    35,177
    
    
    
    29,914Diluted
    
    
    44,760
    
    
    
    29,914Comprehensive Income:Net income (loss)
    
    $
    1,478
    
    
    $
    (419
    )Foreign currency translation adjustments
    
    
    240
    
    
    
    (1,008
    )Unrealized gain (loss) on marketable securities
    
    
    78
    
    
    
    (401
    )Comprehensive Income (loss)
    
    $
    1,796
    
    
    $
    (1,828
    )
  31




---



##### Table of Contents



GLOBAL MED TECHNOLOGIES, INC. AND SUBSIDIARIES
 
 CONSOLIDATED STATEMENT OF STOCKHOLDERS EQUITY
 (In thousands)
 AccumulatedotherPreferred Stock Series
    
    Common Stock
    
    Additional
    
    Accumulated
    
    ComprehensiveShares
    
    Amount
    
    Shares
    
    Dollars
    
    Paid-in-Capital
    
    Deficit
    
    Income (Loss)
    
    TotalBalances, December 31,
2007
    
    
    8
    
    
    $
    7,735
    
    
    
    26,674
    
    
    $
    267
    
    
    $
    54,288
    
    
    $
    (59,360
    )
    
    
    
    
    
    $
    2,930Stock-based compensation
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    327
    
    
    
    
    
    
    
    
    
    
    
    327Exercise of options for cash
    
    
    
    
    
    
    
    
    
    
    651
    
    
    
    6
    
    
    
    484
    
    
    
    
    
    
    
    
    
    
    
    490Cashless exercise of options
    
    
    
    
    
    
    
    
    
    
    565
    
    
    
    5
    
    
    
    (5
    )
    
    
    
    
    
    
    
    
    
    
    0Issuance of common stock in
connection with Inlog
acquisition
    
    
    
    
    
    
    
    
    
    
    451
    
    
    
    5
    
    
    
    563
    
    
    
    
    
    
    
    
    
    
    
    568Issuance of common stock in
connection with eDonor
acquisition
    
    
    
    
    
    
    
    
    
    
    1,180
    
    
    
    12
    
    
    
    1,488
    
    
    
    
    
    
    
    
    
    
    
    1,500Exercise of warrants for cash
    
    
    
    
    
    
    
    
    
    
    1,308
    
    
    
    13
    
    
    
    948
    
    
    
    
    
    
    
    
    
    
    
    961Cashless exercise of warrants
    
    
    
    
    
    
    
    
    
    
    695
    
    
    
    7
    
    
    
    (7
    )
    
    
    
    
    
    
    
    
    
    
    0Issuance of warrants in
connection with financing
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    81
    
    
    
    
    
    
    
    
    
    
    
    81Vesting of restricted stock
    
    
    
    
    
    
    
    
    
    
    61
    
    
    
    
    
    
    
    86
    
    
    
    
    
    
    
    
    
    
    
    86Excess tax benefits associated
with stock options
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    296
    
    
    
    
    
    
    
    
    
    
    
    296Conversion of Series A
Preferred Stock to common
shares
    
    
    (2
    )
    
    
    (1,787
    )
    
    
    2,482
    
    
    
    25
    
    
    
    1,762
    
    
    
    
    
    
    
    
    
    
    
    0Other comprehensive loss- net
unrealized loss/gain
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (401
    )
    
    
    (401
    )Translation adjustment
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (1,008
    )
    
    
    (1,008
    )Net Loss
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (419
    )
    
    
    
    
    
    
    (419
    )Balances, December 31,
2008
    
    
    6
    
    
    $
    5,948
    
    
    
    34,067
    
    
    $
    340
    
    
    $
    60,311
    
    
    $
    (59,779
    )
    
    $
    (1,409
    )
    
    $
    5,411
 
 32




---



##### Table of Contents



GLOBAL MED TECHNOLOGIES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF STOCKHOLDERS EQUITY (continued)
(In thousands)
 Paid-in-
    
    
    Accumulated
    
    
    Accumulated
Other 
Comprehensive
 IncomeShares
    
    
    Amount
    
    
    Shares
    
    
    Dollars
    
    
    Capital
    
    
    Deficit
    
    
    (Loss)
    
    
    TotalBalances, December 31,
2008
    
    
    6
    
    
    $
    5,948
    
    
    
    34,067
    
    
    $
    340
    
    
    $
    60,311
    
    
    $
    (59,779
    )
    
    $
    (1,409
    )
    
    $
    5,411Stock-based compensation
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    184
    
    
    
    
    
    
    
    
    
    
    
    184Exercise of options for cash
    
    
    
    
    
    
    
    
    
    
    315
    
    
    
    3
    
    
    
    201
    
    
    
    
    
    
    
    
    
    
    
    204Cashless exercise of options
    
    
    
    
    
    
    
    
    
    
    453
    
    
    
    5
    
    
    
    (243
    )
    
    
    
    
    
    
    
    
    
    
    (238
    )Issuance of common stock in
connection with Inlog
acquisition
    
    
    
    
    
    
    
    
    
    
    517
    
    
    
    5
    
    
    
    646
    
    
    
    
    
    
    
    
    
    
    
    651Vesting of restricted stock
    
    
    
    
    
    
    
    
    
    
    46
    
    
    
    1
    
    
    
    48
    
    
    
    
    
    
    
    
    
    
    
    49Conversion of Series A
Preferred Stock to common
shares
    
    
    (1
    )
    
    
    (888
    )
    
    
    1,233
    
    
    
    12
    
    
    
    876
    
    
    
    
    
    
    
    
    
    
    
    0Excess tax benefits associated
with stock options
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    235
    
    
    
    
    
    
    
    
    
    
    
    235Other comprehensive loss-
net unrealized loss/gain
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    78
    
    
    
    78Translation adjustment
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    240
    
    
    
    240Net income
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    1,478
    
    
    
    
    
    
    
    1,478Balances, December 31,
2009
    
    
    5
    
    
    $
    5,060
    
    
    
    36,631
    
    
    $
    366
    
    
    $
    62,258
    
    
    $
    (58,301
    )
    
    $
    (1,091
    )
    
    $
    8,292
  33




---



##### Table of Contents



GLOBAL MED TECHNOLOGIES, INC. AND SUBSIDIARIES
 
 CONSOLIDATED STATEMENTS OF CASH FLOWS
 (In thousands)
 Year Ended December 31,2009
    
    
    2008CASH FLOWS FROM OPERATING ACTIVITIES:Net income (loss)
    
    $
    1,478
    
    
    $
    (419
    )Adjustments to reconcile net income (loss) to net cash provided by
(used in) operating activities:Depreciation and amortization
    
    
    1,418
    
    
    
    794Amortization of financing costs
    
    
    209
    
    
    
    80Stock-based compensation expense
    
    
    233
    
    
    
    413Excess tax benefit associated with stock options
    
    
    (235
    )
    
    
    (296
    )Deferred income taxes
    
    
    (96
    )
    
    
    (102
    )Bad debt expense
    
    
    87
    
    
    
    72Changes in operating assets and liabilities, net of effects of
acquisitions:Accounts receivable-trade
    
    
    42
    
    
    
    (1,427
    )Accrued revenues
    
    
    (497
    )
    
    
    486Prepaid expenses and other assets
    
    
    266
    
    
    
    (633
    )Accounts payable
    
    
    (197
    )
    
    
    364Accrued expenses
    
    
    529
    
    
    
    (329
    )Litigation accrual
    
    
    (1,004
    )
    
    
    Accrued income tax payable
    
    
    429
    
    
    
    (468
    )Prepaid income taxes
    
    
    (62
    )
    
    
    Deferred revenue
    
    
    193
    
    
    
    515Net cash provided (used in) by operating activities
    
    
    2,793
    
    
    
    (950
    )CASH FLOWS FROM INVESTING ACTIVITIES:Acquisitions, net of cash acquired
    
    
    (132
    )
    
    
    (9,471
    )Purchases of property and equipment
    
    
    (201
    )
    
    
    (565
    )Capitalized software development costs and other intangibles
    
    
    (260
    )
    
    
    (284
    )Proceeds from sale of marketable securities
    
    
    
    
    
    
    283Net cash used in investing activities
    
    
    (593
    )
    
    
    (10,037
    )
 
 34




---



##### Table of Contents



GLOBAL MED TECHNOLOGIES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)
(In thousands)
 Year Ended December 31,2009
    
    
    2008CASH FLOWS FROM FINANCING ACTIVITIES:Exercise of options and warrants for cash
    
    
    206
    
    
    
    1,451Excess tax benefit associated with equity compensation
    
    
    235
    
    
    
    296Tax associated with cashless exercise options
    
    
    (241
    )
    
    
    Proceeds from long-term debt, net of financing costs
    
    
    
    
    
    
    7,363Repayment of long-term debt and capital lease
obligations, net of proceeds
    
    
    (1,673
    )
    
    
    (180
    )Net cash (used in) provided by financing activities
    
    
    (1,473
    )
    
    
    8,930NET INCREASE
(DECREASE) IN CASH AND CASH EQUIVALENTS
    
    
    727
    
    
    
    (2,057
    )Effect of exchange rate changes on cash
    
    
    39
    
    
    
    (219
    )CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR
    
    
    4,472
    
    
    
    6,748CASH AND CASH EQUIVALENTS AT END OF YEAR
    
    $
    5,238
    
    
    $
    4,472SUPPLEMENTAL DISCLOSURESNon-cash financing activities:Conversion of Series A Preferred Stock to shares of common stock
    
    $
    888
    
    
    $
    1,787Fair value of common stock issued in connection with Inlog
acquisition
    
    
    651
    
    
    
    568Fair value of common stock issued in connection with eDonor
acquisition
    
    
    
    
    
    
    1,500Fair value of obligation to sellers related to Inlog acquisition
    
    
    
    
    
    
    2,257Cash paid for the period:Cash paid for income taxes
    
    $
    111
    
    
    $
    749Cash paid for interest
    
    $
    567
    
    
    $
    318
  35




---



##### Table of Contents



GLOBAL MED TECHNOLOGIES, INC. AND SUBSIDIARIES
 
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
          Investments  Debt and Equity Securities Accounting for
Certain Investments in Debt and Equity Securities
   36




---



##### Table of Contents



Software 
Cost of Sales and Services Accounting for the Costs of
Computer Software to be Sold, Leased or Otherwise Marketed)
    37




---



##### Table of Contents



Intangibles  Goodwill and Other Goodwill and Other Intangible Assets).
        38




---



##### Table of Contents



Software  Revenue Recognition Software Revenue Recognition
         39




---



##### Table of Contents



2009
    
    
    2008Weighted average number of shares used in the basic
earnings per share computation
    
    
    35,177
    
    
    
    29,914Effect of dilutive securities:Common stock options
    
    
    693
    
    
    
    2,655Common stock warrants
    
    
    491
    
    
    
    3,912Preferred stock convertible securities
    
    
    7,590
    
    
    
    9,884Contingently issuable shares associated
with Inlog acquisition
    
    
    768
    
    
    
    514Restricted stock
    
    
    41
    
    
    
    40Dilutive securities
    
    
    9,583
    
    
    
    17,005Adjusted weighted average number of shares used in
diluted earnings per share computation
    
    
    44,760
    
    
    
    46,919
   Stock Compensation Stock-based Compensation
  December 31,2009
    
    
    2008Assumptions:Dividend Yield
    
    
    0
    %
    
    
    0
    %Volatility factor
    
    
    101.6
    %
    
    
    100
    %Risk free interest rate
    
    
    3.29
    %
    
    
    2.4
    %Expected Life of Option (in years)
    
    
    10
    
    
    
    10
 40




---



##### Table of Contents



TM
  (Included in Accounting Standards Codification ASC 805 Business Combination, previously known as
SFAS , Business Combinations). Business Combinations
 41




---



##### Table of Contents



(Included in Accounting Standards Codification ASC 810 Consolidation, previously known as ). Noncontrolling Interests in
Consolidated Financial Statements, an amendment of ARB No. 51
 (Included in Accounting Standards Codification ASC 820 Fair Value Measurements and Disclosures,
previously known as SFAS 157, Fair Value Measurements). Fair Value Measurements and Disclosures (Topic 820): Improving Disclosures about Fair
Value Measurements Fair Value Measurements and Disclosures
 (Included in Accounting Standards Codification ASC 820 Effective Date of FASB Statement No. 157,
previously known as FASB Staff Position (FSP) SFAS No. 157-2, Effective Date of FASB Statement
No. 157). Effective Date of FASB Statement No. 157
 (Included in Accounting Standards Codification ASC 350 previously known as FSP SFAS No. 142- an
amendment of Goodwill and Other intangible Assets). Goodwill and Other intangible Assets
 (Included in Accounting Standards Codification ASC 825 Disclosures about Fair Value of Financial
Instrument previously known as FSP 107-1 and APB 28-1 Interim Disclosures
about Fair Value of Financial Instruments, Disclosures about Fair Value
of Financial Instruments Interim Financial Reporting,
 42




---



##### Table of Contents



(Included in Accounting Standards Codification ASC 855 Subsequent Events previously known SFAS
165). Subsequent Events
 (Included in Accounting Standards Update ASU 2009-13 Revenue Recognition) 605 Multiple-Deliverable Revenue
Arrangements
 NOTE 2. ACQUISITIONS
   
    43




---



##### Table of Contents



Inlog
    
    
    eDonorSummary of purchase price:Cash paid
    
    $
    7,520
    
    
    $
    3,500Common stock
    
    
    1,219
    
    
    
    1,500Transaction costs
    
    
    1,200
    
    
    
    1439,939
    
    
    
    5,143Fixed future consideration to be paid:Cash payment due by June 26, 2010 (1)
    
    
    629Common stock or cash to be issued by June 26, 2010
    
    
    651Discount on future consideration
    
    
    (98
    )$
    11,121
    
    
    $
    5,143
 (1)
    
    Underlying payments are to be made in Euros, which have been converted to U.S. dollars
using the exchange rate as of the acquisition date.  Inlog
    
    
    eDonorCash and marketable securities
    
    $
    2,885
    
    
    $
    276Trade and unbilled receivables, net
    
    
    3,542
    
    
    
    14Other current assets
    
    
    674
    
    
    
    27Equipment, furniture and fixtures
    
    
    842
    
    
    
    70Intangible assets and acquired software
    
    
    3,722
    
    
    
    2,480Goodwill
    
    
    6,744
    
    
    
    2,402Accounts payable and other accrued expenses
    
    
    (3,683
    )
    
    
    Deferred revenue
    
    
    (1,393
    )
    
    
    (126
    )Deferred tax liability
    
    
    (1,504
    )
    
    
    Long-term debt
    
    
    (865
    )
    
    
    $
    10,964
    
    
    $
    5,143
   44




---



##### Table of Contents



Year Ended December 31,2009
    
    2008Revenues
    
    $
    31,788
    
    
    $
    30,976Net income (loss)
    
    $
    1,478
    
    
    $
    (654
    )Basic net income (loss) per share
    
    $
    0.04
    
    
    $
    (0.02
    )Diluted net income (loss) per share
    
    $
    0.03
    
    
    $
    (0.02
    )
   NOTE 3. PROPERTY AND EQUIPMENT
  December 31,2009
    
    
    2008Computer hardware and software
    
    $
    2,908
    
    
    $
    2,551Furniture and fixtures
    
    
    687
    
    
    
    691Leasehold improvements
    
    
    613
    
    
    
    665Machinery and equipment
    
    
    609
    
    
    
    5964,817
    
    
    
    4,503Less accumulated depreciation and amortization
    
    
    (3,491
    )
    
    
    (3,118
    )Property and equipment, net
    
    $
    1,326
    
    
    $
    1,385
  45




---



##### Table of Contents



NOTE 4. GOODWILL AND INTANGIBLES
  Software
    
    
    Intangibles
    
    
    GoodwillNet balance at December 31, 2007
    
    $
    173
    
    
    $
    
    
    
    $
    Additions
    
    
    4,655
    
    
    
    1,831
    
    
    
    9,116Amortization expense
    
    
    (404
    )
    
    
    (91
    )
    
    
    Net foreign currency translation
    
    
    (327
    )
    
    
    (98
    )
    
    
    (774
    )Net balance at December 31, 2008
    
    $
    4,097
    
    
    $
    1,642
    
    
    $
    8,342Additions
    
    
    198
    
    
    
    63
    
    
    
    32Amortization expense
    
    
    (801
    )
    
    
    (198
    )
    
    
    Net foreign currency translation
    
    
    61
    
    
    
    19
    
    
    
    211Net balance at December 31, 2009
    
    $
    3,555
    
    
    $
    1,526
    
    
    $
    8,585Gross balance at December 31, 2009
    
    $
    8,116
    
    
    $
    1,821
    
    
    $
    8,585Accumulated amortization
    
    
    (4,561
    )
    
    
    (295
    )
    
    
    Net balance at December 31, 2009
    
    $
    3,555
    
    
    $
    1,526
    
    
    $
    8,585
  Year ending December 31, 2010
    
    $
    899
    
    
    $
    203Year ending December 31, 2011
    
    
    899
    
    
    
    203Year ending December 31, 2012
    
    
    899
    
    
    
    203Year ending December 31, 2013
    
    
    571
    
    
    
    157Year ending December 31, 2014
    
    
    228
    
    
    
    111Thereafter
    
    
    59
    
    
    
    649$
    3,555
    
    
    $
    1,526
  Goodwill and Indefinite-Lived Assets
    46




---



##### Table of Contents



NOTE 5. AVAILABLE FOR SALE SECURITIES
      Cost
    
    Unrealized loss
    
    Fair ValueDecember 31, 2008Marketable equity security
    
    $
    613
    
    
    $
    (425
    )
    
    $
    188December 31, 2009Marketable equity security
    
    $
    613
    
    
    $
    (346
    )
    
    $
    267
 NOTE 6. LONG-TERM DEBT AND OBLIGATIONS TO INLOG SELLERS
  47




---



##### Table of Contents



December 31,2009
    
    
    2008Revolving line of credit
    
    $
    990
    
    
    $
    983Term loan
    
    
    3,936
    
    
    
    4,898Subordinated term loan
    
    
    1,420
    
    
    
    1,400Inlog notes payable and capital leases
    
    
    596
    
    
    
    639Capital leases
    
    
    58
    
    
    
    117,000
    
    
    
    7,931Less  current portion
    
    
    (1,257
    )
    
    
    (1,168
    )$
    5,743
    
    
    $
    6,763
       48




---



##### Table of Contents



December 31,2009
    
    
    2008Cash payments due Inlog sellers
    
    $
    553
    
    
    $
    1,040Stock issuable to Inlog sellers
    
    
    629
    
    
    
    1,2171,182
    
    
    
    2,257Less  current portion
    
    
    (1,182
    )
    
    
    (1,167
    )$
    
    
    
    $
    1,090
 
   49




---



##### Table of Contents



Long-termDebt, Notes
    
    
    
    
    
    
    Less:Payable
    
    
    Obligations
    
    
    Amounts
    
    
    Presentand Capital
    
    
    to Inlog
    
    
    Representing
    
    
    Value ofLeases
    
    
    Sellers (1)
    
    
    Interest
    
    
    Payments2010
    
    
    1,291
    
    
    
    1,207
    
    
    
    (53
    )
    
    
    2,4452011
    
    
    3,684
    
    
    
    
    
    
    
    (107
    )
    
    
    3,5772012
    
    
    1,105
    
    
    
    
    
    
    
    (12
    )
    
    
    1,0932013
    
    
    1,059
    
    
    
    
    
    
    
    (4
    )
    
    
    1,0552014
    
    
    12
    
    
    
    
    
    
    
    
    
    
    
    12$
    7,151
    
    
    $
    1,207
    
    
    $
    (176
    )
    
    $
    8,182
 
 (1)
    
    Includes obligations payable in the Companys common stock with a market value of
$651 thousand in 2010. NOTE 7. STOCKHOLDERS EQUITY
 Options and Warrants Exercised
   Conversion of Preferred Stock to Common Stock
   50




---



##### Table of Contents



NOTE 8. INCOME TAXES
  2009
    
    
    2008Current:Federal
    
    $
    (48
    )
    
    $
    236State
    
    
    
    
    
    
    165Deferred:Federal
    
    
    561
    
    
    
    (54
    )State
    
    
    1,123
    
    
    
    (108
    )Foreign
    
    
    (252
    )
    
    
    (182
    )Change in valuation allowance
    
    
    (865
    )
    
    
    242Total income tax expense
    
    $
    519
    
    
    $
    299
  2009
    
    
    2008Expected federal tax provision
    
    $
    679
    
    
    $
    (41
    )Effect of permanent differences
    
    
    37
    
    
    
    59Change in valuation allowance for deferred tax assets
    
    
    (865
    )
    
    
    242State tax benefit, net of federal provision
    
    
    257
    
    
    
    38Foreign taxes at other rates
    
    
    (74
    )
    
    
    1Expiration of net operating losses
    
    
    485
    
    
    
    Income tax expense
    
    $
    519
    
    
    $
    299
  2009
    
    
    2008Deferred tax assets:Net operating loss carry forwards
    
    $
    8,097
    
    
    $
    8,027Allowance for uncollectible accounts and notes
receivable
    
    
    110
    
    
    
    323Non qualified stock option exercises
    
    
    
    
    
    
    22Unearned revenue
    
    
    1,438
    
    
    
    2,511Accrued expenses and other
    
    
    281
    
    
    
    677Total deferred tax assets
    
    
    9,926
    
    
    
    11,560Valuation allowance
    
    
    (8,628
    )
    
    
    (9,746
    )Deferred tax assets
    
    $
    1,298
    
    
    $
    1,814
 51




---



##### Table of Contents



2009
    
    
    2008Deferred tax liability:Depreciation and other
    
    $
    26
    
    
    $
    45State taxes
    
    
    425
    
    
    
    750Capitalized software development
    
    
    177
    
    
    
    177Foreign deferred tax liability, net
    
    
    1,211
    
    
    
    1,211Deferred tax liability
    
    $
    1,839
    
    
    $
    2,183
  2009
    
    2008U.S.
    
    $
    3,606
    
    
    
    308Foreign
    
    
    (1,609
    )
    
    
    (428
    )Income (loss) before income taxes
    
    $
    1,997
    
    
    $
    (120
    )
    .
 NOTE 9. STOCK OPTION PLANS, WARRANTS, AND STOCK COMPENSATION PLAN
 Stock Options
  52




---



##### Table of Contents



53




---



##### Table of Contents



Options Outstanding
    
    Exercisable OptionsAggregate
    
    
    
    
    
    
    
    
    
    
    
    
    
    AggregateIntrinsic
    
    
    
    
    
    
    
    
    
    
    
    
    
    IntrinsicRange of exercise prices
    
    Amount
    
    Value
    
    Price*
    
    Life*
    
    Amount
    
    Value
    
    Price*
    
    Life*$0.45 - 0.66
    
    
    2,560,500
    
    
    
    
    
    
    $
    0.58
    
    
    
    2.97
    
    
    
    2,560,500
    
    
    
    
    
    
    $
    0.58
    
    
    
    2.97$0.66 - 0.87
    
    
    431,437
    
    
    
    
    
    
    $
    0.75
    
    
    
    7.21
    
    
    
    328,105
    
    
    
    
    
    
    $
    0.74
    
    
    
    6.93$0.87 - 1.08
    
    
    235,000
    
    
    
    
    
    
    $
    1.00
    
    
    
    3.73
    
    
    
    235,000
    
    
    
    
    
    
    $
    1.00
    
    
    
    3.73$1.08 - 1.29
    
    
    2,695,000
    
    
    
    
    
    
    $
    1.15
    
    
    
    5.96
    
    
    
    2,234,550
    
    
    
    
    
    
    $
    1.15
    
    
    
    5.96$1.29 - 1.50
    
    
    500,000
    
    
    
    
    
    
    $
    1.39
    
    
    
    0.11
    
    
    
    500,000
    
    
    
    
    
    
    $
    1.39
    
    
    
    0.11Total December 31, 2009
    
    
    6,421,937
    
    
    $
    530,322
    
    
    $
    0.91
    
    
    
    4.31
    
    
    
    5,858,155
    
    
    $
    528,572
    
    
    $
    0.89
    
    
    
    4.12
  2009
    
    2008Options
    
    Price*
    
    Options
    
    Price*Outstanding, beginning of year
    
    
    8,597,136
    
    
    $
    0.83
    
    
    
    10,823,602
    
    
    $
    0.82Granted
    
    
    140,001
    
    
    
    0.75
    
    
    
    200,000
    
    
    
    0.89Forfeited/cancelled
    
    
    (1,547,049
    )
    
    
    0.64
    
    
    
    (1,210,843
    )
    
    
    0.79Exercised
    
    
    (768,151
    )
    
    
    0.60
    
    
    
    (1,215,623
    )
    
    
    0.75Outstanding, end of year
    
    
    6,421,937
    
    
    $
    0.91
    
    
    
    8,597,136
    
    
    $
    0.83
 
 *
    
    Price reflects the weighted average exercise price and life represents the weighted-average
remaining contractual term. Restricted Stock
  WeightedAverage GrantShares
    
    
    Date Fair ValueNonvested at January 1, 2009
    
    
    72,003
    
    
    $
    1.27Canceled or expired
    
    
    (3,471
    )
    
    
    1.27Vested
    
    
    (40,751
    )
    
    
    1.27Nonvested at December 31, 2009
    
    
    27,781
    
    
    $
    1.27
 54




---



##### Table of Contents



Warrants
  Balance at December 31, 2007
    
    
    12,340,626
    
    
    $
    0.69Canceled
    
    
    (304,878
    )
    
    
    0.25Exercised
    
    
    (2,003,456
    )
    
    
    0.57Issuances
    
    
    105,000
    
    
    
    1.25Balance at December 31, 2008
    
    
    10,137,292
    
    
    $
    0.73Canceled
    
    
    (65,000
    )
    
    
    0.55Balance at December 31, 2009
    
    
    10,072,292
    
    
    $
    0.73
  NOTE 10. RELATED PARTY TRANSACTIONS
    NOTE 11. COMMITMENTS AND CONTINGENCIES
 Leases
  For the year ending December 31,2010
    
    $
    7482011
    
    
    6362012
    
    
    5832013
    
    
    4652014
    
    
    194Thereafter
    
    
    $
    2,626
 55




---



##### Table of Contents



Litigation
 Global Med Technologies, Inc. v.
Donnie L. Jackson, Jr., et al
  s
   56




---



##### Table of Contents



Carmelo J. Corica, Joseph F. Sham and Robert OBrien
v. Michael Ruxin et al., Case Nos. 10CV673, 10CV801, 10CV802
  Employment Agreements
  NOTE 12. Subsequent Events
 Merger Agreement
  57




---



##### Table of Contents



Merger
  Conversion of Series A
  
 ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
  
 ITEM 9A. CONTROLS AND PROCEDURES
  ITEM 9A(T). CONTROLS AND PROCEDURES
 Evaluation of Disclosure Controls and Procedures.
  58




---



##### Table of Contents



Changes in Internal Controls over Financial Reporting.
  Managements Annual Report on Internal Control over Financial Reporting
     
 ITEM 9B. OTHER INFORMATION
 Earnings Release
   59




---



##### Table of Contents



PART III
 
 ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
 Identification of Directors and Executive Officers
  Name
    
    Age
    
    Position(s)Executive OfficersMichael I. Ruxin, M.D.
    
    
    64
    
    
    Chief Executive Officer and ChairmanThomas F. Marcinek
    
    
    56
    
    
    President, Chief Operating Officer and DirectorDarren P. Craig
    
    
    45
    
    
    Acting Chief Financial OfficerTimothy J. Pellegrini
    
    
    47
    
    
    Sr. Vice President, Chief Operating Officer, WyndgateGerald F. Willman, Jr.
    
    
    52
    
    
    Sr. Vice President of Sales and Marketing, Europe, ME, AsiaWilliam Scott Dustin
    
    
    61
    
    
    Sr. Vice President of Sales and Marketing, AmericasMiklos Csore
    
    
    45
    
    
    Sr. Vice President of Research and DevelopmentDirectorsRobert R. Gilmore
    
    
    58
    
    
    DirectorSarah L. Eames
    
    
    51
    
    
    DirectorT. Kendall Ken Hunt
    
    
    66
    
    
    Director
   60




---



##### Table of Contents



Michael I. Ruxin, M.D
 Thomas F. Marcinek
 Darren P. Craig , CPA
 Timothy J. Pellegrini
 Gerald F. Willman, Jr .
 61




---



##### Table of Contents



William Scott Dustin
 Miklos Csore
 Robert R. Gilmore, CPA
 Sarah L. Eames
 T. Kendall Ken Hunt
 Director Qualifications and Experience.
 62




---



##### Table of Contents



Ruxin
    
    Marcinek
    
    Gilmore
    
    Eames
    
    HuntExperience, Qualification, Skill or AttributeProfessional standing in chosen field
    
    x
    
    x
    
    x
    
    x
    
    xExpertise in healthcare or related industry
    
    x
    
    x
    
    
    
    xExpertise in technology or related industry
    
    x
    
    x
    
    x
    
    
    
    xAudit Committee Financial Expert (actual or potential)
    
    
    
    
    
    x
    
    xCivic and community involvement
    
    
    
    
    
    
    
    x
    
    xOther public company experience
    
    x
    
    
    
    x
    
    
    
    xDiversity by race, gender or culture
    
    
    
    
    
    
    
    xSpecific skills/knowledge:-healthcare
    
    x
    
    x
    
    
    
    x-technology
    
    x
    
    x
    
    x
    
    
    
    x-governance
    
    x
    
    
    
    x
    
    x
    
    x
 Board Leadership Structure
    The Boards Role in Risk Oversight
    Audit Committee .
 63




---



##### Table of Contents



Section 16(a) Beneficial Ownership Reporting Compliance
  Code of Ethics
  
 ITEM 11. EXECUTIVE COMPENSATION
 Summary Compensation Table
  64




---



##### Table of Contents



Nonequity
    
    
    NonqualifiedStock
    
    
    Option
    
    
    incentive plan
    
    
    deferred
    
    
    AllName and
    
    
    
    
    
    
    
    Bonus
    
    
    Awards
    
    
    Awards
    
    
    compensation
    
    
    compensation
    
    
    otherprincipal position
    
    Year
    
    Salary ($)
    
    
    ($)
    
    
    ($)
    
    
    ($)
    
    
    ($)
    
    
    earnings ($)
    
    
    ($)
    
    
    Total ($)Michael I. Ruxin,
    
    2009
    
    
    432,062
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    58,328
    *
    
    
    
    
    
    
    
    
    
    
    490,390M.D.
Chairman and CEO
    
    2008
    
    
    419,109
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    43,456
    
    
    
    
    
    
    
    12,846
    (1)
    
    
    462,565Thomas F. Marcinek
    
    2009
    
    
    285,500
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    38,543
    *
    
    
    
    
    
    
    
    
    
    
    324,043President and COO
    
    2008
    
    
    278,951
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    17,451
    
    
    
    
    
    
    
    
    
    
    
    296,402William Scott Dustin
    
    2009
    
    
    127,050
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    97,523
    
    
    
    
    
    
    
    
    
    
    
    224,573Senior Vice
President of Sales
and Marketing,
Americas
    
    2008
    
    
    126,585
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    130,579
    
    
    
    
    
    
    
    
    
    
    
    257,164Darren P. Craig
Acting Chief
Financial Officer
    
    2009
    
    
    163,500
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    11,340
    *
    
    
    
    
    
    
    
    
    
    
    174,840
 
 *
    
    The nonequity incentive plan compensation earnings, a form of incentive compensation, for fiscal
year 2009 are subject to adjustment based on the final review by the Companys Compensation
Committee.(1)
    
    In 2008, Dr. Ruxin received $5,912 in life insurance premiums, an annual car allowance of $2,956
and $3,978 in medical reimbursements.   65




---



##### Table of Contents



Outstanding Equity Awards at Fiscal Year-end Table
  OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END
 Option AwardsNumber of
    
    
    Number ofSecurities
    
    
    SecuritiesUnderlying
    
    
    UnderlyingUnexercised
    
    
    Unexercised
    
    
    OptionOptions
    
    
    Options
    
    
    Exercise
    
    
    Option(#)
    
    
    (#)
    
    
    Price
    
    
    ExpirationName
    
    Exercisable
    
    
    Unexercisable
    
    
    ($)
    
    
    DateMichael I. Ruxin,
M.D.
    
    
    500,000
    (1)
    
    
    
    
    
    
    0.58
    
    
    
    10/25/2012Chairman and Chief Executive Officer
    
    
    250,000
    (2)
    
    
    
    
    
    
    1.15
    
    
    
    12/16/2015Thomas F. Marcinek
    
    
    500,000
    (1)
    
    
    
    
    
    
    0.58
    
    
    
    10/12/2012President and Chief
Operating Officer
    
    
    250,000
    (2)
    
    
    
    
    
    
    1.15
    
    
    
    12/16/2015Darren P. Craig,
    
    
    50,000
    (3)
    
    
    
    
    
    
    1.05
    
    
    
    10/23/2010Acting Chief Financial
Officer
    
    
    150,000
    (2)
    
    
    
    
    
    
    0.58
    
    
    
    10/25/2012275,000
    (2)
    
    
    225,000
    (6)
    
    
    1.15
    
    
    
    12/16/2015William Scott Dustin,
    
    
    200,000
    (4)
    
    
    
    
    
    
    0.60
    
    
    
    9/27/2014Senior Vice President
of Sales and
Marketing, Americas
    
    
    75,000
    (5)
    
    
    25,000
    (7)
    
    
    1.15
    
    
    
    12/16/2015
 
 (1)
    
    These options were exercisable or vested over time and were fully exercisable on December
16, 2005.(2)
    
    These options were exercisable on December 16, 2005.(3)
    
    These options were exercisable on October 23, 2005.(4)
    
    These options were exercisable on September 27, 2008.(5)
    
    These options were exercisable on December 16, 2008.(6)
    
    These options will be exercisable at consummation of the Merger.(7)
    
    Each year on December 16th, and continuing until 2014, 5,000 of these options will
become exercisable.  66




---



##### Table of Contents



Long-Term Incentive Plan (LTIP) Awards Table
  Employment Agreements and Post-termination Payments
 Michael I. Ruxin, M.D.
  Thomas F. Marcinek
  Darren Craig
  67




---



##### Table of Contents



William Scott Dustin
  Non-equity Incentive Compensation
    Director Compensation
  th
 68




---



##### Table of Contents



Fees
    
    
    
    
    
    
    
    
    
    Non-Equity
    
    NonqualifiedEarned or
    
    Stock
    
    Options
    
    Incentive Plan
    
    Deferred
    
    All OtherPaid in
    
    Awards
    
    Awards
    
    Compensation
    
    Compensation
    
    Compensation
    
    TotalName
    
    Cash ($)
    
    ($)
    
    ($)
    
    ($)
    
    Earnings ($)
    
    ($)
    
    ($)Robert R.
Gilmore(1)
    
    $
    46,000
    
    
    $
    
    
    
    $
    35,000
    
    
    $
    
    
    
    $
    
    
    
    $
    
    
    
    $
    81,000Sarah L. Eames(2)
    
    $
    42,500
    
    
    $
    
    
    
    $
    35,000
    
    
    $
    
    
    
    $
    
    
    
    $
    
    
    
    $
    77,500T. Kendall Hunt(3)
    
    $
    38,500
    
    
    $
    
    
    
    $
    35,000
    
    
    $
    
    
    
    $
    
    
    
    $
    
    
    
    $
    73,500
 
 (1)
    
    As of December 31, 2009, Mr. Gilmore had an aggregate of 117,762 options to purchase Common
Stock outstanding, of which 19,444 were unvested.(2)
    
    As of December 31, 2009, Ms. Eames had an aggregate of 117,762 options to purchase Common Stock
outstanding, of which 19,444 were unvested.(3)
    
    As of December 31, 2009, Mr. Hunt had an aggregate of 105,913 options to purchase Common Stock
outstanding, of which 19,444 were unvested. Indemnification Agreements
  
 ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED
STOCKHOLDER MATTERS
  Common Stock Beneficially
    
    Percentage of Common StockName and Address
    
    Owned(1)
    
    Beneficially Owned(1)Michael I. Ruxin, M.D.
    
    
    1,900,579
    (2) (3)
    
    
    4.85
    %12600 W. Colfax, Suite C-420Lakewood, CO 80215Thomas F. Marcinek
    
    
    1,308,204
    (2) (3)
    
    
    3.34
    %4925 Robert J. Mathews ParkwaySuite 100El Dorado Hills, CA 95762
 69




---



##### Table of Contents



Common Stock Beneficially
    
    Percentage of Common StockName and Address
    
    Owned(1)
    
    Beneficially Owned(1)Darren P. Craig
    
    
    475,000
    (2) (3)
    
    
    1.22
    %4925 Robert J. Mathews ParkwaySuite 100El Dorado Hills, CA 95762William Scott Dustin
    
    
    275,000
    (2) (3)
    
    
    *4925 Robert J. Mathews ParkwaySuite 100El Dorado Hills, CA 95762Robert R. Gilmore
    
    
    141,433
    (2) (3)
    
    
    *12600 W. Colfax, Suite C-420Lakewood, CO 80215Sarah L. Eames
    
    
    141,433
    (2) (3)
    
    
    *12600 W. Colfax, Suite C-420Lakewood, CO 80215T. Kendall Hunt
    
    
    159,584
    (2) (3) (4)
    
    
    *12600 W. Colfax, Suite C-420Lakewood, CO 80215All
Directors and Executive Officers
    
    
    4,401,233
    (2) (3)
    
    
    10.73
    %as
a Group (7 persons)Victory Park Special
    
    
    4,876,765
    (5)
    
    
    12.68
    %Situations Master Fund, Ltd.c/o Walkers SPV LimitedWalker House87 Mary StreetGeorgetown, Grand CaymanCayman Islands KY1 9002Crestview Capital Master, LLC
    
    
    4,073,356
    (6)
    
    
    9.99
    %95 Revere Drive, Suite ANorthbrook, IL 60062Shepherd
Investments International, Ltd.
    
    
    3,582,167
    (7)
    
    
    8.83
    %3600 South Lake DriveSt. Francis, WI 53235
 
 *
    
    Represents holdings of less than one percent (1%).(1)
    
    The number of shares outstanding used in calculating the applicable percentage of beneficial
ownership is based on 38,445,725 shares of Common Stock outstanding as of March 8, 2010
together with securities exercisable or convertible into shares of Common Stock within 60 days
of March 8, 2010. Shares of Common Stock subject to securities which are currently exercisable
or convertible within 60 days of March 8, 2010 are deemed outstanding for computing the
percentage of the person or entity holding such securities but are not deemed outstanding for
computing the percentage of any other person or entity.(2)
    
    Each of these individuals possesses sole voting and dispositive power over the shares
beneficially owned.(3)
    
    Shares beneficially owned includes options that are currently exercisable or exercisable
within 60 days.(4)
    
    Includes 30,000 shares held by the T. Kendall Hunt Trust, of which Mr. Hunt is the trustee,
and 27,559 fully vested restricted stock units. Mr. Hunt, a member of the Companys Board of
Directors, is affiliated with Victory Park Capital Advisors, LLC (Victory Park CA). The T. Kendall Hunt Trust
has a 5% ownership of Victory Park GP, LLC, and a 5% ownership of Victory Park CA. Mr. Hunt is on the Advisory Board of Victory Park CA, but
is not an officer of that entity. Mr. Hunt is an investor in Victory Park Special Situations LP as a limited
partner. Mr. Hunt has no decision making authority with respect to Victory Park CA, Victory Park GP, LLC, or any of their respective affiliated funds.(5)
    
    Based partially on information contained in the Schedule 13D/A jointly filed by Victory
Park CA, Victory Park Special Situations Master Fund, Ltd.
(Victory Park Special Situations), Jacob Capital, L.L.C. (Jacob Capital) and Richard Levy
pursuant to the Exchange Act on February 1, 2010 and on information contained in the Form 4
jointly filed by Victory Park Special Situations, Victory Park CA, Jacob Capital and Richard Levy
on October 2, 2008, each of which may not be current as of the date of this Annual Report on Form 10-K. Victory Park CA shares voting and dispositive power over the shares it owns with Jacob
Capital, Victory Park Special Situations and Richard Levy. Victory Park Special Situations
holds warrants that would be convertible into 4,125,000 shares of Common Stock and 3,960
shares of Preferred Stock, which constitute all of the outstanding shares of Preferred Stock
as of February 26, 2010 that would be convertible into 5,500,000 shares of Common Stock if not
for certain restrictions on conversion such that the holder may only exercise the warrants or
convert the Preferred Stock so the beneficial ownership by the holder (together with such
holders affiliates) is no 70




---



##### Table of Contents



more than 9.99% of the shares of Common Stock outstanding immediately after giving effect to
such conversion. Accordingly, the shares underlying the warrants and the Preferred Stock
have not been included in the number of shares beneficially owned. Victory Park CA is the
investment manager for Victory Park Special Situations. Jacob Capital is the manager of
Victory Park CA. Richard Levy is the sole member of Jacob Capital. Victory Park CA, Jacob
Capital and Richard Levy disclaim beneficial ownership of the securities except to the
extent of their pecuniary interest therein.(6)
    
    Based partially on information contained in the Schedule 13G/A jointly filed by Crestview
Capital Master, LLC (Crestview) and Crestview Capital Partners, LLC (Crestview Partners)
pursuant to the Exchange Act on February 14, 2008, which may not be current as of the date of
this Annual Report on Form 10-K. Crestview holds warrants that would be convertible into 2,833,334
shares of Common Stock, if not for certain restrictions on conversion, such that the holder
may only exercise the warrants so that the beneficial ownership by the holder (together with
such holders affiliates) is no more than 9.99% of the shares of Common Stock outstanding
immediately after giving effect to such conversion. These warrants, up to the 9.99%
threshold, are included in the number of shares of Common Stock beneficially owned by
Crestview. On February 3, 2010, Crestview converted 1,100 shares of Preferred Stock, held in
the name of National Financial Services, LLC, Crestviews clearing agent, into 1,527,778
shares of Common Stock. Crestview Partners is the sole manager of Crestview, and as such has
the power to direct the vote and to direct the disposition of investments beneficially owned
by Crestview, including the Common Stock, and thus may also be deemed to beneficially own the
Common Stock beneficially owned by Crestview. Stewart Flink, Robert Hoyt and Daniel Warsh,
each of whom are United States citizens, are the managers of Crestview Partners, and as such
may be deemed to share the power to vote and to dispose of investments beneficially owned by
Crestview Partners, including the Common Stock; however, each expressly disclaims beneficial
ownership of such shares of Common Stock.(7)
    
    Based partially on information contained in the Schedule 13G/A jointly filed by Michael A. Roth
and Brian J. Stark with respect to shares held by Shepherd Investments International, Ltd.
(Shepherd) pursuant to the Exchange Act on February 16, 2010, which may not be current as of
the date of this Annual Report on Form 10-K. Shepherd holds warrants that would be convertible
into 2,125,000 shares of Common Stock if not for certain restrictions on conversion, such that
the holder may only exercise the warrants so that beneficial ownership by the holder
(together with such holders affiliates) is no more than 9.99% of the shares of Common Stock
outstanding immediately after giving effect to such conversion. These warrants are included in the number of shares of Common Stock beneficially owned by
Shepherd. Michael A. Roth and Brian J. Stark direct the management of Stark Offshore
Management, LLC (Stark Offshore), which acts as the investment manager and has sole power to
direct the management of Shepherd. As the managing members of Stark Offshore, Michael A.
Roth and Brian J. Stark possess shared voting and dispositive power over all of the foregoing
shares. Michael A. Roth and Brian J. Stark disclaim beneficial ownership of such shares of
Common Stock. 
 ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
 Director Independence
  Related Party Transactions
  
 ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
  December 31,2009
    
    
    2008Audit fees (1)
    
    $
    147,945
    
    
    $
    164,581Audit related fees (2)
    
    $
    8,185
    
    
    $
    32,321Tax fees (3)
    
    $
    31,750
    
    
    $
    31,050All other Fees (4)
    
    $
    
    
    
    $
    $
    187,880
    
    
    $
    227,952
 71




---



##### Table of Contents



(1)
    
    Audit Fees:represents the aggregate fees billed or to be billed
for professional services rendered for the audits of the
Companys annual financial statements and for the review of the
financial statements included in the Companys quarterly reports
during such periods, or for services that are normally provided
in connection with statutory and regulatory filings or
engagements.(2)
    
    Audit-Related Fees: represents the aggregate fees billed or to
be billed for assurance and related services, that are reasonably
related to the performance of the audit or review of the
Companys financial statements, but are not included as Audit
Fees.(3)
    
    Tax Fees: represents the aggregate fees billed or to be billed for
professional services rendered for U.S. federal, state and foreign tax
compliance, tax advice and tax planning.(4)
    
    All Other Fees: represents the aggregate fees billed or to be billed consisting of permitted non-audit services.  72




---



##### Table of Contents



PART IV
 
 ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
 Financial Statements:
 Exhibits:
 ExhibitNumber
    
    DESCRIPTION2.1
    
    Agreement and Plan of Merger, dated as of January 31, 2010, by and among Haemonetics, the
Acquisition Sub and the Company. (32)3.1
    
    Amended and Restated Articles of Incorporation, filed June 2, 1995 (1)3.2
    
    Articles of Amendment to the Articles of Incorporation, filed March 5, 1996 (1)3.3
    
    Articles of Amendment to the Articles of Incorporation, filed May 30, 1996 (1)3.4
    
    Bylaws, as amended (27)3.5
    
    Amended and Restated Articles of Incorporation, dated April 16, 2001 (27)4.1
    
    Specimen copy of stock certificate for common stock, $.01 par value (1)10.1
    
    Development Agreement, dated July 12, 1996 between Global Med and The Institute for
Transfusion Medicine, dated July 12, 1996, as amended January 12, 1998 (4)10.2
    
    Office Lease between the Company and Golden Hill Partnership, dated January 11, 1999 (6)10.3
    
    Standard Industrial/Commercial Multi-Tenant Lease between the Company and James W. Cameron,
Jr., dated February 8, 1999 (6)10.4
    
    2001 Stock Option Plan (11)*10.5
    
    Amended and Restated 1997 Stock Compensation Plan (12)*10.6
    
    Global Med Technologies, Inc. 2003 Stock Option Plan. (15)*10.7
    
    Articles of Amendment to Articles of Incorporation  Preferred Stock (16)10.8
    
    Code of Ethics and Conduct for Global Med Technologies, Inc. (18)10.9
    
    Securities Purchase Agreement between the purchasers dated December 16, 2005. (20)10.10
    
    Registration Rights Agreement between the registrant and the purchasers dated December 16,
2005. (20)10.11
    
    Stock Purchase Agreement between the Company and GMIL dated December 16, 2005. (20)10.12
    
    Certificate of Designation of Preferences Rights and Limitations of Series A Convertible
Preferred Stock between the registrant and the purchasers dated December 16, 2005. (20)10.13
    
    Common Stock Purchase Warrant between the Company and the purchasers dated December 16,
2005. (20)10.14
    
    Private Placement Agreement between the Company and purchasers dated December 16, 2005. (20)
 73




---



##### Table of Contents



ExhibitNumber
    
    DESCRIPTION10.15
    
    Right of First Notice Agreement between Futuristic Image Builder, Ltd., the purchasers and the
Company dated December 16, 2005. (20)10.16
    
    Right of First Notice Agreement between the shareholders, the purchasers and the Company dated
December 16, 2005. (20)10.17
    
    Private Stock Purchase and Escrow Agreement between the investors, GMIL, and the Company dated
December 16, 2005. (20)10.18
    
    First Amendment to Securities Purchase Agreement (21)10.19
    
    Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of the
Series A Convertible Preferred Stock (21)10.20
    
    Amended and Restated Common Stock Purchase Warrant (21)10.21
    
    First Amendment to Registration Rights Agreement (21)10.22
    
    Loan and Security Agreement dated as of June 17, 2008 between Silicon Valley Bank, Global
Med Technologies, Inc. and PeopleMed.com, Inc. (23)10.23
    
    Intellectual Property Security Agreement dated as of June 17, 2008 between
Silicon Valley Bank, Global Med Technologies, Inc. and PeopleMed.com, Inc. (23)10.24
    
    Executive Employment Agreement dated November 1, 2008 between the Company and Timothy Pellegrini
(29)*10.25
    
    Executive Employment Agreement dated November 1, 2008 between the Company and Gerald Willman (29)*10.26
    
    Executive Employment Agreement dated November 1, 2008 between the Company and Miklos Csore (29)*10.27
    
    Executive Employment Agreement dated November 1, 2008 between the Company and William Scott Dustin
and amendment thereto (29) (34)*10.28
    
    Executive Employment Agreement dated November 1, 2008 between the Company and Darren Craig (31)*10.29
    
    Stock Purchase Agreement dated March 26, 2008 between the Company and Sellers Named Therein
(22)10.30
    
    Second Amendment to Loan and Security Agreement, dated March 19, 2009 between the Company and
Silicon Valley Bank. (28)10.31
    
    Limited Waiver and Amendment No. 2 to Loan and Security Agreement, dated March 19, 2009 between the
Company and Partners for Growth II, L.P. (28)10.32
    
    Amended and Restated Warrant, dated March 19, 2009 between the Company and Partners for Growth II,
L.P. (28)10.33
    
    Confidentiality Agreement, dated as of March 30, 2009, by and between the Company and Haemonetics.
(35)10.34
    
    Loan and Security Agreement dated as of June 17, 2008 between Silicon Valley Bank, Global
Med Technologies, Inc. and PeopleMed.com, Inc. (23)10.35
    
    Security Agreement, dated June 26, 2008 among Global Med Technologies, Inc. and the
Sellers named therein (24)10.36
    
    Loan and Security Agreement dated as of July 18, 2008 among Partners for Growth II, L.P., Global
Med Technologies, Inc. and PeopleMed.com, Inc. (25)10.37
    
    Employment Agreement dated July 30, 2009, between the Company and Michael I. Ruxin, effective
August 1, 2009 (25)*10.38
    
    Asset Purchase Agreement dated July 31, 2009 Between the Company and the Sellers Named Therein (26)10.39
    
    Binding Letter of Intent dated September 15, 2009 between Inlog S.A. and VeriDentia, S.L. (30)
 74




---



##### Table of Contents



ExhibitNumber
    
    DESCRIPTION10.40
    
    Executive Employment Agreement dated November 1, 2009 between the Company and Thomas F. Marcinek
(34)*10.41
    
    Exclusivity Agreement between the Company and Haemonetics, dated as of December 2, 2009. (35)10.42
    
    Extension of Exclusivity Agreement between the Company and Haemonetics, dated as of January 25,
2010 (35)10.43
    
    Form of Indemnification Agreement between the Company and certain of its officers and directors.
(33)14.1
    
    Code of Ethics (18)21.1
    
    Subsidiaries of Registrant23.1
    
    Consent of the Companys Independent Auditors.31.1
    
    Certification of the Chief Executive Officer pursuant to Rule 13a- 14(a) or Rule 15d-14(a) of the
Securities Exchange Act of 1934, as amended.31.2
    
    Certification of the Acting Chief Financial Officer pursuant to Rule 13a- 14(a) or Rule 15d-14(a)
of the Securities Exchange Act of 1934, as amended.32.1
    
    Certification of the Chief Executive Officer pursuant to U.S.C. Section 1350, as adopted, pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002.32.2
    
    Certification of Acting Chief Financial Officer pursuant to U.S.C. Section 1350, as adopted,
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.99.1
    
    Press Release dated November 11, 2009.99.2
    
    Amended Class Action Complaint in the matter of Carmelo J. Corica, Joseph F. Sham and Robert
OBrien v. Michael Ruxin et al., Case Nos. 10CV673, 10CV801, 10CV802
 *
    
    Management contract or compensatory plan or arrangement(1)
    
    The documents identified are incorporated by reference from the Companys Registration Statement on
Form SB-2 (No. 333-11723).(2)-(3)
    
    Not used(4)
    
    Incorporated by reference from the Companys Annual Report on Form 10-KSB for the year ended
December 31, 1997.(5)
    
    Not used.(6)
    
    Incorporated by reference from the Companys Annual Report on Form 10-KSB for the year ended
December 31, 1998.(7) (10)
    
    Not used.(11)
    
    Incorporated by reference from the Companys Registration Statement on Form S-8 (No. 333-60674)(12)
    
    Incorporated by reference from the Companys Registration Statement on Form S-8 (No. 333-60672)(13)-(14)
    
    Not used.(15)
    
    Incorporated by reference from the Companys Form 10-K for the year ended December 31, 2003.(16)
    
    Incorporated by reference from the Companys Form 10-Q for the quarterly period ended June 30, 2004.(17)
    
    Not used.(18)
    
    Incorporated by reference from the Companys Form S-1 (No. 333-121030).(19)
    
    Not used.(20)
    
    Incorporated by reference from the Companys Form 8-K filed on December 20, 2005.(21)
    
    Incorporated by reference to the Companys Form 10-KSB for the year ended December 31, 2005(22)
    
    Incorporated by reference to the Companys Current Report on Form 8-K filed on March 31, 2008(23)
    
    Incorporated by reference to the Companys Current Report on Form 8-K filed on June 20, 2008(24)
    
    Incorporated by reference to the Companys Current Report on Form 8-K filed on July 2, 2008(25)
    
    Incorporated by reference to the Companys Form 10-Q for the quarterly period ended June 30, 2008.
 75




---



##### Table of Contents



(26)
    
    Incorporated by reference to the Companys Current Report on Form 8-K filed on August 6, 2008(27)
    
    Incorporated by reference to the Companys Current Report on Form 8-K filed on November 19, 2008.(28)
    
    Incorporated by reference to the Companys Form 10-K for the year ended December 31, 2008.(29)
    
    Incorporated by referencfe to the Companys Form 10-Q for the quarterly period ended June 30, 2009(30)
    
    Incorporated by reference to the Companys Current Report on Form 8-K filed on September 21, 2009(31)
    
    Incorporated by reference to the Companys Current Report on Form 8-K filed on October 19, 2009.(32)
    
    Incorporated by reference to to the Companys Current Report on Form 8-K filed with the SEC on
February 2, 2010.(33)
    
    Incorporated by reference to the Companys Current Report on Form 8-K filed with the SEC on
February 23, 2010.(34)
    
    Incorporated by reference to the Companys Schedule 14D-9 filed on March 4, 2010.(35)
    
    Incorporated by reference to the Tender Offer Statement on Schedule TO, filed by Haemonetics and
Acquisition Sub with respect to the Company on February 19, 2010.
 76




---



##### Table of Contents



SIGNATURES
  GLOBAL MED TECHNOLOGIES, INC.,
a Colorado CorporationDate: March 16, 2010
    By:
    /s/ Michael I. Ruxin, M.D.Michael I. Ruxin, M.D.Chairman of the Board and Chief Executive Officer  Date: March 16, 2010
    By:
    /s/ Michael I. Ruxin, M.D.Michael I. Ruxin, M.D., Chairman of the Board andChief Executive Officer (Principal Executive Officer) Date:  March 16, 2010
    By:
    /s/ Thomas F. MarcinekThomas F. Marcinek, Director, President andChief Operating Officer Date: March 16, 2010
    By:
    /s/ Darren P. CraigDarren P. Craig, Acting Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) Date: March 16, 2010
    By:
    /s/ T. Kendall HuntT. Kendall Hunt, Director Date:
    By:Sarah L. Eames, Director Date: March 16, 2010
    By:
    /s/ Robert R. GilmoreRobert R. Gilmore, Director 77